Recent molecular and cellular advances in pediatric bone marrow transplantation.
The field of allogeneic transplantation has made vast improvements since its inception in 1968. Improvements in supportive care have greatly improved survival. Delayed immune reconstitution, graft versus host disease, and relapse of disease still pose great obstacles. This article has highlighted novel strategies for using cellular therapy in conjunction with hematopoietic cell transplantation (HCT) that potentially may lead to improved clinical outcomes for patients undergoing HCT in the future.
Talano
Julie-An M
JA
Division of Pediatric Hematology and Oncology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA. jtalano@mail.mcw.edu
Margolis
David A
DA
D004266:DNA Virus Infections / Q000517:prevention & control / Q000628:therapy; D006086:Graft vs Host Disease / Q000175:diagnosis; D020544:Graft vs Leukemia Effect; D018380:Hematopoietic Stem Cell Transplantation / Q000639:trends*; D006801:Humans; D007167:Immunotherapy; D017708:Leukocyte Transfusion; D009369:Neoplasms / Q000628:therapy; D010372:Pediatrics / Q000639:trends*; D013601:T-Lymphocytes / Q000276:immunology; D014777:Virus Diseases / Q000276:immunology / Q000628:therapy